What the evidence says about anxiety treatment

Cognitive behavioral therapy (CBT) is the most studied psychological treatment for anxiety disorders. Systematic reviews report moderate to large effect sizes for CBT versus waitlist or treatment-as-usual across generalized anxiety, social anxiety, panic disorder, and specific phobias.

Exposure-based protocols are a core component of CBT for panic, social anxiety, and specific phobias, and the magnitude of benefit tends to be largest when exposure is delivered in a structured, dose-adequate course. Long-term follow-up data suggest CBT gains are durable for many patients, though relapse remains common and booster sessions are sometimes used.

Guidelines from the APA and NICE place SSRIs and SNRIs as first-line pharmacotherapy for adult anxiety disorders. Meta-analyses of placebo-controlled trials estimate small-to-moderate effect sizes, with response typically emerging over four to twelve weeks. The conditions covered include GAD, social anxiety, panic disorder, and PTSD. No SSRI has been shown to be meaningfully superior to another for anxiety overall.

Buspirone has evidence in generalized anxiety. Benzodiazepines provide rapid symptom relief but are limited by tolerance, dependence, withdrawal risk, and interactions with alcohol and opioids; current guidelines recommend short-term or situational use rather than chronic monotherapy.

New from PsychiatryRx: an interactive, psychiatrist-reviewed guide to how psychiatric medications work in the brain, a patient-facing explainer you can share.

For moderate-to-severe anxiety, combined CBT and SSRI/SNRI therapy is often superior to either treatment alone in the short term, though long-term differences are smaller. Sequencing matters: some patients respond well to medication first and add therapy later; others tolerate exposure-based CBT only after partial pharmacologic response.

Treatment selection should account for patient preference, side-effect tolerance, severity, and access.

A consistent finding across U.S. surveys is that most adults with anxiety disorders don't receive evidence-based care. Barriers include cost, insurance coverage, geographic provider shortages, stigma, and time off work for appointments.

Workforce shortages are particularly acute in rural areas. Psychiatrists also accept insurance at lower rates than most other medical specialties, meaning even insured patients may face substantial out-of-pocket costs to access care.

Comparative effectiveness studies and systematic reviews of telepsychiatry for anxiety report outcomes comparable to in-person care for assessment, medication management, and several psychotherapies. Telepsychiatry has expanded access in rural and provider-shortage areas and has shown high patient satisfaction.

Evidence for fully virtual exposure-based protocols continues to develop.

Population-level evidence identifies which treatments produce the largest average improvement, but it can't tell any one patient which option will work for them. Treatment decisions depend on diagnosis, prior treatment response, side-effect tolerance, comorbidities, life circumstances, access, and preference.

For more on why trial averages do not predict individual response, see Why outcomes vary between individuals.